CSTL - Earnings call transcript Q2 2021 | Castle Biosciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to Castle Biosciences Second Quarter 2021 Conference Call.

As a reminder, today's call is being recorded.

We will begin today's call with opening remarks and introductions, followed by a question-and-answer session. I would like to turn the call over to Camilo Zucaro, Executive Director, Investor Relations and Corporate Communications. Please go ahead.

Camilla Zuckero

operator. you, Thank everyone. Good afternoon, Castle call. Biosciences' financial to quarter second conference results Welcome XXXX

Joining of and call to Information Founder, may be accurate. Derek Castle's page if of me is today XXXX. X, President call A the replay only Chief of company's Therefore, Officer, today, August this transcript Investor are Maetzold; Financial longer Chief Frank the on Stokes. listening the available recorded this call, you the speaks as and Officer, of approximately no today's will for or reading any be on time-sensitive three information website recording Relations weeks. Executive

we today pursuant Private events future impact financial Before and that discussed may you contain including remind performance of projections are pandemic Act or made the the forward-looking harbor Securities like of and Litigation the I safe future to begin, company, XXXX. assumptions or related to regarding of information some the of of expectations COVID-XX provisions the other to Reform the would statements

of cause are can revise quarter differ statements in Forward-looking there ended of Securities assume forward-looking are inherent and change. from reports and XXXX, be involve forward-looking These detail company's and and and risks current and statements results forward-looking only A Form and XX, these described could for to These Quarterly update those in June uncertainties obligation expectations the and speak to will as Commission. in circumstances the in on realized. number statements upon Exchange in the other statements. or no that other risks we risks these the no these Report uncertainties, contemplated and with actual assurances as be filed and documents today, results based the company's XX-Q contained factors materially statements factors

directly We today margin, the provide financial believe information are performance. non-GAAP addition, of such assessing information the in the GAAP non-GAAP release measures. on today, most Reconciliations been gross of call the end now in revenue has company's over Relations adjusted posted discussed flow earnings financial which the adjusted Derek. I these useful of the which page our revenue comparable supplemental cash includes and will metrics In issued measures these to financial tables Investor the some earlier and are of at website. as financial measures our turn to presented metrics

Derek Maetzold

you, quarter discuss you growth like call. call quarter Thank Castle's Castle and financial performance. additional and us on the by second our will for start to earnings Camilla, today then results progress and highlights Thank XXXX from against team. recent will detail thanking the I'd provide everyone. I afternoon good for Frank our afternoon, joining today's This initiatives.

that million, in-person and an trading we mean delivered conduct dermatologic gene - our the record furthering initiatives updates quarter exceptional, work able a long-term in side, position Say, sales exceptional had we On engaged each ex is XXXX. we're clinician to the the to by I sales that continue second continue over quarter we second up volume team's hard It And a our of our entered XXXX, our we increase their revenue our quarter test the as open customers as of practices. tests. total our growth clinical fully contributed quarter. of execute first to in as second report XX% proprietary leader differently quarter on for In to a single in the quarter profile diagnostics. $XX.X

was second XXX% our in XXXX. revenue, to increase $XX.X a Additionally, effects delivered excluding the of over periods, adjusted the test of adjustments related quarter revenue prior million,

understand are data. delivered, the remaining gains strong informative last gains delivered performance DecisionDx-Melanoma million. test in to to cutaneous $XX the growth raising upon compared reports XX% guidance during year DecisionDx-Melanoma comparing be our of full significant may XXXX. reflects momentum, As report We revenue we us gene provided XXXX. million reports for to million less analysis This of Due XXXX despite revenue same X,XXX test historical the the X,XXX for expected May XXXX year. by provided may pandemic our period of XXXX in $XX reports guidance $XX to you recall, in second X,XXX to in market based previously year full million impacted diagnoses continued the we includes diagnoses of to to our compared approximately test guidance in as melanoma $XX XXXX that levels believe our expression second below total growth of XXXX to the profile quarter We compared the in XX% year-over-year that third-party quarter both well as hardest given penetration. we The and

is a XXXX. mentioned. XX% of the quarter to our decrease is the volume over report melanoma different So, just XXXX provide the And I a increase DecisionDx-Melanoma diagnoses second perspective in face for of second ongoing quarter this cutaneous

be spread believe potential momentum positive we the impacts variants, the of have seen of certain future including of continue. we Although we cannot will COVID-XX any emergence and

dermatology diagnostic representatives XXs. sales Additionally, and skin surgical cancer who oncologists skin force sales approximately three of of to the size all And in primary and our surgeons followed product Mohs in by head cancer our point, calling and existing call Utilizing and selling expansion surgeons And dermatologists on including work surgeons, is mid a beginning each clinician lines. our the channels is neck as on focused dermatopathologists. sales of outside our July complete. doubled our team X, sales

levels first XXXX return XXXX, XX%. of our three our for doubled are that for promotionally XXXX the in-person XXXX. extent we still totals positioned of in quarter continued specifically, we've Number for the of our the that we quarter first exceeded XXXX of number that from over sales XXXX. calls penetration the to doubling variables. the although, three improve. to and quarter a being our in growth than sales is in of continued the quarter approximately to market the combined two, below nearly of is dermatology more average up per of already just promotional to we of XXXX believe were per Number seen positively that team. a remainder of believe all half the these first in-person, impacted second with peer-to-peer have continues XX% three, number in by seeing programs XX% it continued quarter our we pre-COVID second the of increase by one, is day Thus, are second responsive market reps We due calls well to And focused compared for variables And

or test. diagnosed our Turning pleased with the a one Castle more differentiator dermatologic this rate for cell tests tests. for patients position rest second risk DecisionDx-SCC clear in high-risk factors. GEP XXX in carcinoma delivered We adoption quarter of remain the and leader of cutaneous one We reports for as squamous XXXX. extremely with our We believe is

test We continue as to value and through have expect diagnostic well SCC commercial our seen leveraging see comprehensive to dermatologic for our channels as offering. established for

specifically clinicians the we ordered who that Melanoma. [ph] ordered SCC are and over Third-party also melanoma more for XX, six Mohs us that DecisionDx-SCC XXXX, DecisionDx diagnose first ended field. both And data leverage months providing seeing with dermatologists XX% XX% in of June the surgeons of shows approximately

patients either We heavily cutaneous cohort in located and neck risk evidence year's than on developed International was regional squamous independent cell current carcinoma p XX neck. Neck of and American At DecisionDx-SCC X of from patients when patients are Castle Archival data Neck XX.X%, high test or Class with expected, data-driven complements Furthermore, three-year risk different presented regression the staging. XXX a new XXth X to value distant of of Cancer, we of Class a DecisionDx-SCC an in and with less result, and/or compared patients result found test from Cox SCC Head methods invest result study. assessment the a rates different The survival Society test or predictor specimens Multivariate XX.X%, received had analysis, free XX metastasis and development. XB the the Conference risk company decision as were overall AJCC biological and a this metastatic clinical or XX.X% moderate Class head metastasis. in tumor biological a evidence-based biological that sites we significantly primary Head on risk low-risk data high head included or associated Patients had to and the demonstrating test a be X.XXXX. respectively, using XX%

stratification compared would say more AJCC ratio hazard in had and staging, increase the staging X.XX alone. to compared X.XX I importantly, higher to AJCC a substantially demonstrating Additionally with risk DecisionDx-SCC

it as payers. growth both in investing our clinicians of we of profile We test all evidence remains component tests, reimbursement expression of development continue continue strategy, our for a commercial by - gene and our plan adoption supporting by key to

there the for complete previously this Palmetto discussed, in As assurances, must under which XXXX. or plan that to posted no remind Noridian be a third technical acceptance dossier to as XXXX. But test for was timeframe confirmation of and there no although, you can in being in the specific of Palmetto I submission We determination of second is be the we've to received And quarter Noridian quarter submitted continued XXXX. LCD our draft we assessment operate. coverage of DecisionDx-SCC local and

or offering for suspicious. lesions, also difficult-to-diagnose our unequivocal, discuss test Now let's called uncertain comprehensive melanocytic diagnostic

characterizing As in myPath we risk to malignant DiffDx-Melanoma, diagnose rare diagnostic test acquire designed in cases in Melanoma April, has in an malignancy. and for be recall, Melanoma, DecisionDx, and profile expression and comprehensive to objective closed late difficult to provide a test myPath may you deal and intermediate melanocytic May. gene these to plans the or dermatopathologist our announced dermatologist lesions to our offering benign, likely

lesion, be diagnostic to can lesion. nothing XXX a require In reduce using XX% biopsies node or biopsies a diagnosis a diagnose by additional of benign or or estimated the diagnosed the dermatopathologists malignant diagnosis to with lesions implemented. preferred of to determined plan uncertainty well. on biopsy you, over the other are the US. characteristics melanoma microscopic definitive these do would do the as is local ancillary difficult remind me These is reached. X definitive at pursue plan lesions traditional of a constantly histopathology. million minimum procedure Thus, testing that that case a it depth case not XX% wide annually Thankfully, up depending and patient's this malignant, on the important commission melanocytic and either be suspected benign the traditional determined It is excision of in of are analyses. approximately there and so can before treatment in Let as receive Whereas generally lesion, sentinel treatment

our let's So and the myPath about talk acquisition the myPath Myriad Laboratory test. Melanoma of Myriad

began we to difficult on our ago As own provide you clarity test development improved years may recall, unmet this address lesions. diagnose need DiffDx-Melanoma medical a few to around to

included our orders to as a In report sensitivity more being profile having intermediate and of low of than addition a out test as small target specificity, the to technical result. failure both result of XX% test rate criteria that developing a able test high well of a is product

the and and Our dermatopathologists published perceived rate myPath valued was the rate assessment intermediate the clinicians literature while research that test high. they and of is market being technical test, of failure Melanoma

our As we achieving in target you know, product succeeded profile.

to could were forward clinical a pleased difficult housing advanced quarter, combined test just a offering that test time. determined more difficult of suspicious fantastic and month lesion XXXX use offering use. lesions that population. for full offered combination knew objective However, the including estimated getting offered in provide Myriad intention to we serve competing profile enable to the to Not were record share myPath quarterly as deliver for had us ability Melanoma XXX offering we is a XX% market in pediatrics the even more Medicare of patient to only studies also evidence expression a We and second This quarter that meeting are and manner. wait we tests results. its both it XX-month of myPath to clinically announced providing I period. mention in for for to more additional Furthermore, - also and structure the same making am myPath one pigment when our we serve of investing while were though Myriad to had test actionable number our performance result test we more achievement actual difficult test DiffDx-Melanoma work customers diagnose our divest in available XX to with with significant announce be DiffDx-Melanoma. development reimbursement for in Melanoma successful fourth that From as than have standalone combined penetration, an for Melanoma diagnostic also use Significantly coverage. the to gene patients and for patients DiffDx-Melanoma build is less that quickly. the upgrading we'd ordering would additional able XX% a for reports test delivered and reports we're June, combined the a than of more an test to to when results moved

addition histopathology, In or the NCCN by neoplasms use it's NCCN also those out including profile performance, of gene Conference guidelines. are Cancer following the pointing to of indeterminate testing, melanocytic noting or ancillary tests worth Network supported the expression guidelines tests for this support meaning National

base performance the with call focusing both summary, relating delivering to our we strong guidelines extensive - value and you to through appropriate to should our on additional financial evidence Frank, stockholders. for quarter over our provide and and use commitment In our financial reimbursement execution commercial on on our payment delivered who'll our excellent driving of As expect, initiatives, turn from more stakeholders the now create results. growth is payers of NCCN an I'll a support. already focused detail continuing patients to team

Frank Stokes

Derek, afternoon, and you, everyone. Thank good

a with XXXX we initiatives Castle quarter million delivered the periods. are team quarter. from $XX.X solid unit a $XX.X partially the increased million made to both lower revenue adjustments to Overall, the our the volumes XX% along for enabled and investments have growth rates, and revenue We reported in reflect Melanoma XXXX, of deliver second We pleased Uveal in increase. by tests revenues that DecisionDx quarter report of in of the second higher higher in prior compared DecisionDx-Melanoma strong us execution per related positive to offset

was second Our during XX%, XXXX. of the quarter second quarter the essentially gross to margin flat

periods, the Our to second test reports adjusted delivered gross XX% XXXX. compared margin, prior excluding associated intangible with the asset amortization for in of of effects and revenue XX% was quarter

to per amortization we be asset approximately quarter. expect forward, Going of intangible acquired the $XXX,XXX

Our these were million sales, increase The XX, XXXX, same year. the period quarter driver total increases for increased in XXXX. quarter studies. by expense compared of to associated which personnel in associated of million $XX.X run ended for functions. the additional of as team operating marketing higher R&D expenses, teams the cost was $XX.X increase as the administrative Derek million $XX.X headcount and the The for conferences million of $X.X attributable the in increased last well June including largest in second and travel and These salaries, SG&A to to to primarily increased headcount higher three our were primarily in-person by support compared personnel costs costs XXXX months as was costs into in events, June large XXXX It with same our training compensation. with returns part stock-based XX, higher events costs remainder as sales SG&A attributable as the XXXX personnel commercial and and associated with compared as period well incurred in benefits our manage clinical to was primarily higher costs include to the bonuses, studies mentioned. our to which associated attributable expansion to of

As initiatives. are activities are part we've of our a making we discussed, the growth in our R&D key investments

XXXX million products costs for growth. is SG&A, June compared quarter expense, commercial XX, for further which to $X.X We our for June of totaled near ended and increase compensation us support ended the to sales, R&D which Total allocated and as $X.X expect non-cash XXXX. continue R&D our million the quarter among XX, to we we expense believe stock-based position well long-term initiatives, pipeline and

stock-based well compensation stock increases valuations in higher periods post-IPO further reflecting due in additional expense both as awards outstanding expect headcount. as our future to option in We growth

to a for for $X.X $X.XX of in Our to share XXXX and net million working for compared $XX.X $XX.X the to XXXX in $X.X of to share loss cash offset for to of quarter for second June million a Diluted second common second compared per million the months loss the Operating same the net net of It was charges. common quarter XXXX. loss, portion positive the recruitment ended share loss quarter XXXX. diluted quarter XX, negative attributable period a the was attributable million $X.XX was capital primarily stockholders attributable share was stockholders to XXXX of Medicare second a six loss per compared the of XXXX. for partially non-cash by flow the increases payment of requirements advance of

that in prior-year payment. the benefited the $X.X cash advance beginning payment - receipt the the flow with associated recoupment advance seat recall This Medicare million You'll from of the began. of operating April, year

As XX, XX, balance the myPath million the primarily XXXX, XXXX cash in been six June associated with were during million recoupment. Melanoma. $X.X has a for of the Investing ended $XX months of June to flows applied payment acquisition

June Finally, equivalents we cash of no XXXX had million $XXX cash debt. and and XX, at

revenue As the to have continue the the half of raised we the year, over of current million of company our year. to belief the guidance the the annual trends recovery $XX million for rest of performance look that the $XX first and to year reflect to should remainder the the we

We I'll order around patients our evidence our and Derek. team expansion, progression to back which pipeline of all invest call our in clinicians, continue turn the plans, continue growth create and to in commercial to development now value revolve aggressively stockholders. tests for to

Derek Maetzold

and our the team. quarter highest an revenue in emphasize a attributed that continued second us us coupled second Castle taken impact company, momentum the Their our can and commitment extremely revenue this quarter. to I'd business test continue tests strong dedication next evidence be GAAP record across level purpose-driven proprietary and make to adjusted each our of of to summary, we in results our have single into lives dermatologic cancer are for support record to our quarter patients other for you in with gene profile expression your our enabled with Castle. like In and for translated diseases continued execution Thank in Operator, and entire on continued high are we volume development concludes Frank. pleased skin unmet drive performance now remarks. needs. you, second to and Q&A. with the our This Thank clinical with commercial interest ready

Operator

Certainly.

proceed. with now will [Operator first question We Catherine the Schulte from Please begin session. The Q&A Instructions] Baird. R.W. is

Catherine Schulte

we Hey, get for guys. what guess, delta Congrats that on of impact the balance is on you guidance assumptions and July in embedded the first, trends can rep I thoughts melanoma the access your variant the in quarter for just questions. thanks the and on kind diagnoses your see and are what year? your of

Derek Maetzold

So, we week. July pull didn't last just closed

country early feedback is Our see we it's noise we data the at rep aren't necessarily that across anything as way purchase least terms diagnosis at although in access, to in corners of in would qualitative is of too expect third-party July. there predicting you look the to seeing and terms

That going we that. of would assuming So that well terms quarter see could alter saw right guidance as second to between about per could we being medical to XXXX at XQ modest as be hearing a impact in severity few right it you're now be But over down reaction the said, that in was improvement about early, XXXX of I that that we're XX% We diagnoses of this a XQ commerce. anything last that terms in But even without still calls of how to surprised see back third year. access of day in a as shutdown are time we and Catherine. months assuming but are quarter like though there goes significantly still XX%. a guess can't the we're now. point assuming compared it's we're in our

Catherine Schulte

Great. then coverage meetings need data reopened the has existing those And Okay. how confident they your to criteria? did MolDx And that that for are go. DecisionDx-Melanoma LCD open reaffirm you the

Derek Maetzold

maybe question last first. So,

of and put in which Medicaid are back I they're where should position otherwise that any was ready don't the but change WPSG you sort wraps is articles here that Medicare have posted the LCDs second that draft have other critical don't anything that presume of a intelligence time. see a into think would think I quarter to themselves couple I and So, this that see say we the result we point in the and And in in up that coverage.

the think no we that was of actual in presentations. attended in terms meetings questions negative or participated there discussions I or

succinctly by of now. I to ago half the and out data opportunity XX, of XX think number to publications existing They now. using year, that and wealth that ourselves made as year reinforce of made customers quite there we what and an they ago the had year, get a a a coverage strong as half year well support across a a

So well, add the different the our to want anything you I any guess, think perspective. say no I - than, from Franklin, would I indication and went meetings do comments?

Frank Stokes

I agree.

Catherine Schulte

Okay. Maybe last one for me.

are? that recently Any for can Your two noted on indications those indications. additional pipeline XX-Q studies new on, new tests you color share for what started you

Frank Stokes

yet, it competitive that. Not it's now, we're we we'll for when indications when to to the detail bit time appropriate some We'll we - reasons. right not just talk at Catherine. more - disclosing about little a - the for we're But think look -

Catherine Schulte

Thank great. you. Okay,

Operator

next is Lake Capital The Markets. Street with question Thank Schulte. from Thomas Flaten proceed. Ms. you, Please

Thomas Flaten

quarter and Hey, questions the guys. Thanks well. on congrats as taking for the

you in sites was I AD and Just, in, on psoriasis have us bringing a cetera? that report and new progress terms project give guys quick of if could ongoing et the wondering you

Derek Maetzold

Yeah. quantitative Sure, here. not qualitative only,

the So number we locked a dermatologists, from through of thoughtful our in first half of our not steering the other only input complete central the clinical up year. back protocol scientists, committee, was The completed, IRB. but

in doesn't I up in we and But cancer kind opening that skin quite on interest team saying so I and would involved with operations approval. a now hand programs qualitative of with I would raise count. say under maybe of veracity I up but and of their IRB and kind been our far? maybe small basis, has the sites And that be guess. recruiting so things of centers of seen can cell process our never the also in are people I high-risk We were the some squamous we've that diagnostics, melanoma contract And or done XXXX test. we've think XXXX, clinical any exciting say research cutaneous

we're that the unmet So getting in we solve for that our here such input correct fantastic advisors and us. gain It's were a assessment some our if patient that going this. that be be could need to in for tells of is KOL a me huge you there care which should

would that So, and go early some seeing progression, centers chat. I of say, in our perhaps terms enrolled. time but and provide far, But numbers and recruitment. terms patients in nothing in exceeding targets internal of We'll we of things next terms are we're so actually size it's

Thomas Flaten

me. more just then And one for Great.

rate the going know lot out team I run a folks Given any everything we field or of out for months expanded kind XX that's thoughts know only XX new performance new field a on you new there might that to do and you see that production had six on you've have have of when weeks to expect team in five, given or [indiscernible]. there's there

Derek Maetzold

historically post-hire. expect come XXX% of to would have times fully so effective we what months probably six Frank would non-COVID in Yeah or people kind say I effective in five,

out national here and field meeting kind April-May-ish in training together regroup just July came the to their in Phase entire had largely onboard march a time force Xth beginning X of August sort before completed think these the of July. period I X. So of We individuals

be I move up. have think able say for data any I I should that would don't that. we to

that retrenchment that to side that access third that in assumptions probably fourth of doctors so go surprised don't quarter still think that more So, we timing of just of our Catherine's we the which are patient impact on based for. be includes I that we be a guidance would to the on there's group revised the back to or account see flip would than visits the rep of positive a kind But question by going quarter

quarter. on running? would we're continued quarter I XQ So hard I but five a we see there. would promotional earlier I you seeking access going or hit out right, that's Frank? we compared plus the probably be to to think in or to that impacts year a six drilling are The would XXXX real is minus to I months see should assume not? continued and as commented progression But we how question third four start compared do So fourth seeing second seeing far, Are when or

Frank Stokes

I agree.

Thomas Flaten

All right. Congrats on guys. Thanks, quarter. the

Derek Maetzold

Thanks, Thomas.

Operator

Mr. you, from Sung question Ji Flaten. The proceed. BTIG. next with Please Thank is Nam

Sung Ji Nam

Thanks Hi. questions the on taking for and quarter. congrats the

able about in it? hear to love guys you're to For available? the expecting kind not talk between it's with myPath already and we'd Melanoma. cadence the myPath or from volume this that if about of terms terms then how in you if Also there post-acquisition if of rest the be and we just are is into tests could year DiffDx-Melanoma different contribution you that split might as platform impressive playing know the very talk myPath obviously Melanoma with how one-month model you Is heading you volume backlog out it if the your or you know of of for positioning DiffDx-Melanoma could the

Derek Maetzold

Yeah.

front have in don't not any I think did meant was of me at relevant. mention backlog I I don't we here of I as our of to are well don't I said much So and split going don't being probably tests. That there a be as a forces forces forward know either kind it acquisition. of waiting all. sense Myriad have if that people field on kind were the think don't but that. I impending less

these but if that's position the not case how we some I'm tests. demand So sure pent-up forward maybe but or there there was going

the these better something mean of the first now than So do our perspective alone. I before of what just what's we both think we and of that assets and kind can that have for doing was on does patient to could us for core best it focus

from I in better was think that accuracy by don't They fact [indiscernible] on was had over that would I developed there is clearly argue overall the more much different than I statistics evidence think Myriad or years. had test published our that of our be and We could and we in back we with launched were data more better but set. data had pediatric of that it slightly in the level DiffDx-Melanoma November. validation more they uncomfortable

So developed test till additional we chose data. to pediatric population the even not we

overall present dermatologists customers dramatic you're head think if diagnosis also which is or both we diagnose. is I an pathologists hey are difficult So month uncertain to our and have this this to beginning scratching you say your to how

you're melanoma. to wrong want don't but also it to case in call malignant benign call You it leap big it's a

is an for option Our you. test

Now why unless test to the for us ahead around myPath you report melanoma XX%, think myPath you if offer result that we'd test go can No published to result of just I a the other like that is test to time an we if in about or to to intermediate backup that also XX% tests, and run test is And run score out our our can we test. run or as DiffDx-Melanoma literature DiffDx-Melanoma ahead a of the we on data. which Melanoma object what is get fails go indeterminate of melanoma based my myPath do to us mountain reason. to and

uncertain XX% out the would which malignant of good with doctor? the time, have That's give ability we're an go having to us a in June think even diagnoses. discussion that to able having make that we're you around be So were take it the rather clarity physicians. the actionable to pretty or Wouldn't to show than report XX% we you able that's above And result, and upgrade we to would so of XX%. just agree and month benign

it care. for the as as that's good does us. best right long call patient alive, it's think I the for we're because make, And to

Now already is as an back that, test It LCD Melanoma test existing as of myPath on ADLT you the the already end know. has as established an well.

does through that pull at So quite reimbursement us on Medicare the least for substantially. side

and we So - And of expect would a patient test differential of I good - all it's the care would test it end because the told ordering minority - result. are day, probably the the at that outcome intermediate around that I test is of of a bulk for it's those - Melanoma non-reportable process, for myPath have the of time you. being, the organize just the are be really or order for - myPath failure to they - that - the an DiffDx, are be being if tests

maybe adjustments develop Now myPath answer DecisionDx-Melanoma questions? that are transparent populations in your case of we that evidence, our find outperforms which out may we'll very make the customers. as Does to we additional test, fashion test a there in

Sung Ji Nam

think, I Yeah. so, yeah.

Derek Maetzold

Oh I know I know. -

for wise… So modeling

Sung Ji Nam

Sorry.

Frank Stokes

go becomes course, and wise - Yeah, jump this, probably probably guess - - forward. would But of numbers second so get you And - would not I us more I from Derek. quarter say, would to you quarter first tangible going let I out. I would modeling that I quarter. would ahead of say third get course,

Sung Ji Nam

just getting Got for the it. you the SEC we'd guideline payers, love helpful. making - the especially mentioned have just I up the inclusion the more one test for - know That's Melanoma? the to expert super with the You as hear recommendations DecisionDx-SCC follow And - you panel recent and then KOL that progress the we're received NCCN commercial with DiffDx-Melanoma well. for the myPath

to kind we'd kind with private how of payers? progressing hear love those are of Just the conversations

Derek Maetzold

Yeah.

So interactions customers. moved June of when run our July it putting diagnostic of got - comprehensive out differential business, We and late probably first over guess things test both and on the well it DiffDx-Melanoma kind the myPath the side our we only test. we're the began offering, could of I on well, includes which to all call those

see to that. early too how impact we it's think I So

that is that of moving there time, is for our lead tests forward paid that managed because myPath wasn't test folks care that Myriad up much since Melanoma the attention divestment been that's at fall is least by belief. the sense my last have strategic Now since offered

from I So ground to we're zero starting think something interesting.

database But guideline think a I we success on But be that as coverage is accelerate only it's that fairly on against third a July. Medicare June, our So started would comment Sung-Ji, they're of except quarter, early hope certainly to failure a or to pointing early here quarter the also not late that one that NCCN heavy move that my I of but and through focus base. low only should fourth team. think too inclusion substantial kind

are cell as forward of moving that squamous well. effort on we terms In carcinoma,

claim and paid part Our And sort in was one-off in would revenue. of accruing of internal claim by XXXX. the why getting basis on that's appealing that be basis successful we models we a reason a aren't by

to are be to be example would could a perspective want for historical Our LCD commercial significant players that sort see something draft likely for of until being they hold back Medicare posted. that and

I some an with is that at solution. would like a volume looks high be and of article that looking opportunity to to XXXX frank nice be influential see early and that to progress. together we But I of coming So need in I physicians and have better was you, something the terms in this still say KOLs better would recognizing agree there us very is really think in sort

Sung Ji Nam

so much. Great. Thanks

Operator

questions back Thank at for to Ms. pass remarks. I'll now you, this will additional are Derek Nam. closing waiting it time. There no

Derek Maetzold

joining you second today our concludes Biosciences. us Thank interest earnings This your in quarter again continued XXXX for for call. Castle and

Operator

XXXX concludes Castle the second quarter your Enjoy Biosciences rest day. conference That call. the of

Castle Biosciences (CSTL) 11 Aug 212021 Q2 Earnings call transcript